Ocular Therapeutix names Sanjay Nayak as chief strategy officer

Dr Nayak was the founder and fund manager of a biotech-focused private investment fund, Sentiv Capital.

Ocular Therapeutix / (Logo)

Indian American physician Sanjay Nayak has been appointed as the chief strategy officer of Massachusetts-based biopharmaceutical company, Ocular Therapeutix Inc.

Nayak was the founder and fund manager of a biotech-focused private investment fund, Sentiv Capital, where he integrated over twenty years of expertise in retina and ophthalmology to forge strong connections with industry, investment community and key stakeholders.

Prior to founding Sentiv Capital, Nayak was the founder and managing partner at AnalyzeRx LLC, a healthcare consulting practice focused on delivering qualitative market analytics and competitive strategy to large-cap pharmaceutical and biotechnology companies. 

Nayak also served as the director at Strategic Analysis, Healthcare, which was acquired by IMS Health. His consulting work was focused on pharmaceutical competitive analysis encompassing commercial launch preparations and regulatory, pipeline and clinical trial evaluations.

The Indian American earned his medical degree from Grant Medical College, University of Bombay, India, and a doctorate (PhD) in pharmacology from Drexel University, Philadelphia, Pennsylvania. He has authored and co-authored several publications related to presynaptic receptors in the brain.

Commenting on the appointment, Antony Mattessich, chief executive officer of Ocular Therapeutix, said, “Dr Nayak further strengthens our team, bringing a unique market perspective in retinal disease and ophthalmology from his deep expertise as a strategy consultant and healthcare investor.”

Reacting to his appointment, Nayak said, "Together with the entire Ocular team, we are hoping to address the single biggest unmet need for our patients: a safe, effective, and truly durable therapy for retinal and ophthalmic indications. I am grateful to Antony and Pravin for letting me play a significant role in what we expect will be a transformative time for the company.”